What is Opus Genetics's stock-based comp?

Opus Genetics (IRD) reported stock-based comp of $66K in Q4 2025.

What does stock-based comp mean?

Measures the portion of share-based compensation expenses that are not tax-deductible for income tax purposes. This helps investors understand the tax inefficiency of equity-based incentive programs.

Opus Genetics IRD Stock-Based Comp

Stock-Based Comp at other companies

Target HospitalityTH

$480.25K+171%

USANA Health SciencesUSNA

$343.75K—

Proto LabsPRLB

$76K—

Dine Brands GlobalDIN

$325K—

ePlusPLUS

$608.5K+20.5%

Trex CompanyTREX

$25K+113%

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost.

The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's stock-based comp?: Opus Genetics (IRD) reported stock-based comp of $66K in Q4 2025.
What does stock-based comp mean?: Measures the portion of share-based compensation expenses that are not tax-deductible for income tax purposes. This helps investors understand the tax inefficiency of equity-based incentive programs.